Brochure | April 17, 2019

Container Closure Integrity Testing

Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

Container Closure Integrity

Sterility of parenteral drug products is a regulatory requirement and must be assured during the complete product life cycle. In addition to protection against possible microbial ingress, some drug products may require maintenance of gas impermeability. Assessment of Container Closure Integrity (CCI) is performed during container closure system qualification, drug product manufacture, release, storage and shipment until the end of shelf life. Numerous container closure integrity testing (CCIT) methodologies exist, but there is no preferred method by regulatory authorities. With the revision of USP Chapter <1207>, deterministic approaches are generally favored in order to be independent of the drawbacks of probabilistic testing.

VIEW THE BROCHURE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: